[go: up one dir, main page]

NO20013371L - Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner - Google Patents

Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner

Info

Publication number
NO20013371L
NO20013371L NO20013371A NO20013371A NO20013371L NO 20013371 L NO20013371 L NO 20013371L NO 20013371 A NO20013371 A NO 20013371A NO 20013371 A NO20013371 A NO 20013371A NO 20013371 L NO20013371 L NO 20013371L
Authority
NO
Norway
Prior art keywords
proteins
fusion proteins
nucleotide sequences
export
expression
Prior art date
Application number
NO20013371A
Other languages
English (en)
Other versions
NO20013371D0 (no
Inventor
Kin-Ming Lo
Jinyang Zhang
Stephen D Gillies
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Publication of NO20013371D0 publication Critical patent/NO20013371D0/no
Publication of NO20013371L publication Critical patent/NO20013371L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives nukleotidsekvenser, for eksempel DNA- eller RNA-sekvenser, som koder for et immunglobulin Fc-leptin fusjonsprotein. Nukleotidsekvensene kan innsettes i en egnet ekspresjonsvektor og uttrykkes i pattedyrceller. Det beskrives også en familie av immunglobulin Fc-leptin fusjonsproteiner som kan fremstilles ved ekspresjon av slike nukleotidsekvenser. Fremgangsmåter for anvendelse av slike nukleotidsekvenser og fusjonsproteiner til behandling av tilstander som lindres ved administreringen av leptin, er også beskrevet.
NO20013371A 1999-01-07 2001-07-06 Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner NO20013371L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11507999P 1999-01-07 1999-01-07
PCT/US2000/000352 WO2000040615A2 (en) 1999-01-07 2000-01-07 EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS

Publications (2)

Publication Number Publication Date
NO20013371D0 NO20013371D0 (no) 2001-07-06
NO20013371L true NO20013371L (no) 2001-09-04

Family

ID=22359200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013371A NO20013371L (no) 1999-01-07 2001-07-06 Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner

Country Status (16)

Country Link
US (1) US20040053366A1 (no)
EP (1) EP1141013A2 (no)
JP (1) JP2002534962A (no)
KR (1) KR20020007287A (no)
CN (1) CN1341121A (no)
AU (1) AU778939B2 (no)
BR (1) BR0007414A (no)
CA (1) CA2356401A1 (no)
CZ (1) CZ20012406A3 (no)
HU (1) HUP0105090A2 (no)
ID (1) ID30327A (no)
MX (1) MXPA01006922A (no)
NO (1) NO20013371L (no)
SK (1) SK9432001A3 (no)
WO (1) WO2000040615A2 (no)
ZA (1) ZA200105352B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
HK1038882A1 (zh) * 1998-04-15 2002-04-04 利思进药品公司 通过共同给予血管生成抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
ATE368475T1 (de) 2000-06-29 2007-08-15 Emd Lexigen Res Ct Corp Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
AU2002233340B2 (en) * 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
EP1366455B1 (en) 2001-02-19 2008-07-02 MERCK PATENT GmbH Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
BR0207854A (pt) * 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DK1383785T3 (da) 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
DK1572748T3 (da) * 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
BRPI0406606A (pt) 2003-11-13 2005-12-06 Hanmi Pharm Ind Co Ltd Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
EP1706428B1 (en) * 2004-01-22 2009-09-23 MERCK PATENT GmbH Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
JP4937132B2 (ja) 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫原性の低下したｉｌ−７変種
EP2311880A3 (en) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
US20090175795A1 (en) * 2005-07-29 2009-07-09 Amprotein Corporation Chimeric therapeutic agents
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1801121A1 (en) * 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
PT1966238E (pt) * 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
ES2365046T3 (es) 2005-12-30 2011-09-21 Merck Patent Gmbh Anticuerpos anti-cd19 con inmunogenicidad reducida.
US7846434B2 (en) * 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
US20080227669A1 (en) * 2007-03-12 2008-09-18 Halliburton Energy Services, Inc. Corrosion-inhibiting additives, treatment fluids, and associated methods
JP5622720B2 (ja) 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
JP2012508242A (ja) 2008-11-04 2012-04-05 ニコラオス テザプシディス 神経原線維のもつれ及びアミロイドβの蓄積に起因する進行性認知機能障害を治療するためのレプチン組成物及び方法
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
MX343729B (es) 2011-04-08 2016-11-18 Amgen Inc Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos.
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
MX2014009129A (es) 2012-01-26 2014-11-21 Amgen Inc Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15).
RU2015106812A (ru) * 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
KR20150038511A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 불활성 면역글로불린 Ｆｃ-영역을 갖는 Ｆｃ-융합체로서의 가용성 ＦｃＲ 의 생산 방법 및 그의 용도
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA3014498A1 (en) 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2019143552A1 (en) 2018-01-16 2019-07-25 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
KR20200140878A (ko) 2018-04-09 2020-12-16 암젠 인크 성장 분화 인자 15 융합 단백질
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
AU5539596A (en) * 1995-04-06 1996-10-23 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound

Also Published As

Publication number Publication date
AU778939B2 (en) 2004-12-23
ZA200105352B (en) 2002-06-28
KR20020007287A (ko) 2002-01-26
AU2602500A (en) 2000-07-24
US20040053366A1 (en) 2004-03-18
CA2356401A1 (en) 2000-07-13
JP2002534962A (ja) 2002-10-22
CZ20012406A3 (cs) 2002-03-13
EP1141013A2 (en) 2001-10-10
BR0007414A (pt) 2001-10-16
MXPA01006922A (es) 2002-04-24
NO20013371D0 (no) 2001-07-06
CN1341121A (zh) 2002-03-20
WO2000040615A3 (en) 2000-11-23
WO2000040615A2 (en) 2000-07-13
ID30327A (id) 2001-11-22
HUP0105090A2 (hu) 2002-04-29
SK9432001A3 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
NO20013371L (no) Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner
PL352332A1 (en) Expression and export of interferon-alpha proteins as fc fusion proteins
Worland et al. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae
WO2000011033A3 (en) Expression and export of angiostatin and endostatin as immunofusins
DE69935857D1 (de) Expression eukarotischer peptide in pflanzenplastiden
AU2590901A (en) Il-17 homologous polypeptides and therapeutic uses thereof
AU2003293270A1 (en) Tumor-specific recognition molecules
Senkevich et al. Mapping vaccinia virus DNA replication origins at nucleotide level by deep sequencing
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
WO2021133959A3 (en) Compositions and methods for gamma delta tcr reprogramming using fusion proteins
IL127297A0 (en) Spruce budworm antifreeze proteins genes and methods of using same
WO2002040668A3 (de) Proteine und den proteinen zugrundeliegende dna-sequenzen mit funktion bei entzündungsereignissen
DE69927249D1 (de) Induzierendes alphavirengen- expressionssystem
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
DE69637154D1 (de) Hocheffizientes gewebespezifisches system zur bereitstellung von verbindungen unter verwendung eines streptavidin-protein a fusionsproteins
CN107779474A (zh) 一个表达乳头瘤病毒hpv16的e6和e7自剪切慢病毒载体
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
WO2000052164A3 (en) Potassium channel molecules and uses therefor
HUP0304053A2 (hu) Új expressziós vektorok és azok alkalmazása
CN102702335A (zh) 重组转录激活子样效应因子、转录激活子样效应因子核酸酶及其编码基因及应用
EP0763205A4 (en) NUCLEIC ACID SEQUENCES REGULATING THE EXPRESSION OF LUNG SPECIFIC GENES
CN112553239A (zh) 基于非天然氨基酸的基因组重排调控系统和方法
Qiu et al. Chromosomal Looping‐Based Expression Activation System in Yeast
Wu et al. Self‐cleaving purification tags re‐engineered for rapid Topo® cloning
Palmer et al. Large-scale production of palindrome DNA fragments

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application